Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Kimia Farma Persero Tbk (ISX:KAEF) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
PT Kimia Farma Persero Tbk's Liquidation Value for the quarter that ended in Jun. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kimia Farma Persero Tbk Total Current Assets Related Terms
PT Kimia Farma Persero Tbk Total Current Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kimia Farma Persero Tbk Total Current Assets Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
What does a Total Current Assets of Rp4,767,564 Mil mean?
PT Kimia Farma Persero Tbk (ISX:KAEF) has a Total Current Assets of Rp4,767,564 Mil as of Jun. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for PT Kimia Farma Persero Tbk and its competitors.
Is PT Kimia Farma Persero Tbk's Total Current Assets too high?
PT Kimia Farma Persero Tbk's current Total Current Assets is Rp4,767,564 Mil. Overall, PT Kimia Farma Persero Tbk has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Persero Tbk's Total Current Assets compare to MCK and COR?
PT Kimia Farma Persero Tbk's Total Current Assets of Rp4,767,564 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Medical Distribution company?
A good Total Current Assets depends on the Medical Distribution industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for PT Kimia Farma Persero Tbk and its competitors. PT Kimia Farma Persero Tbk's current Total Current Assets is Rp4,767,564 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Persero Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp579.63, compared to a current price of Rp438.00 — trading 24.4% below its estimated fair value. The current Total Current Assets is Rp4,767,564 Mil. PT Kimia Farma Persero Tbk's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For PT Kimia Farma Persero Tbk (ISX:KAEF), the current Total Current Assets is Rp4,767,564 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Persero Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk stock appears to be undervalued.
The current stock price of Rp438.00 is trading 24.4% below its estimated GF Value™ of Rp579.63.
GuruFocus considers PT Kimia Farma Persero Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
Total Current Assets: Rp4,767,564 Mil
GF Value™: Rp579.63 vs. price of Rp438.00 (24.4% below fair value)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
58GF Score
Get the complete analysis for ISX:KAEF
Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
